Cellebrite DI (NASDAQ:CLBT) Reports Quarterly Results

Cellebrite DI (NASDAQ:CLBT – Get Free Report) reported its quarterly earnings results on Thursday. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02, Briefing.com reports. The company had revenue of $95.70 million for the quarter, compared to analyst estimates of $91.94 million. Cellebrite DI had a positive return on equity of 417.94% and a negative net margin of 32.57%. The company’s revenue for the quarter increased 24.8% year-over-year. During the same period a year ago, the company reported $0.05 EPS. Cellebrite DI has updated its FY 2024 forecast to EPS and its Q3 2024 forecast to EPS.

Cellebrite DI shares rise 9.9%

CLBT shares opened at $16.44 on Friday. The company has a market cap of $3.39 billion, a price-to-earnings ratio of -28.34, a PEG ratio of 1.90, and a beta of 1.50. Cellebrite DI has a 12-month low of $6.36 and a 12-month high of $16.59. The company’s 50-day simple moving average is $12.66 and its 200-day simple moving average is $11.55.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on CLBT stock. Needham & Company LLC raised their price target on Cellebrite DI from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Friday. JPMorgan Chase & Co. raised their price target on Cellebrite DI from $14.00 to $15.00 and gave the company an “overweight” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft raised their price target on shares of Cellebrite DI from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Friday. Bank of America raised their price target on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a report on Friday. Finally, Lake Street Capital raised their price objective on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research note on Friday. Seven analysts have rated the stock with a “buy” rating. According to data from MarketBeat, Cellebrite DI currently has an average rating of “Buy” and an average price target of $17.33.

Read our latest report on Cellebrite DI

About Cellebrite DI

(Get free report)

Cellebrite DI Ltd. develops solutions for regulatory investigations in Europe, the Middle East, Africa, the Americas and Asia Pacific. The company’s DI solutions enable users to collect, review, analyze and manage digital data throughout the investigation cycle for regulatory investigations used in a variety of cases including child exploitation, homicide, counter-terrorism, border control, sexual crimes, human trafficking, corporate security, cryptocurrency and intellectual property theft.

Recommended Articles

Get daily news and reviews for Cellebrite DI – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Cellebrite DI and related companies with MarketBeat.com’s FREE daily email newsletter.